43.05 +0.11 (0.26%)
After hours: 4:22PM EDT
|Bid||42.95 x 1100|
|Ask||44.41 x 1100|
|Day's Range||41.66 - 44.87|
|52 Week Range||36.29 - 49.85|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SALT LAKE CITY, Aug. 22, 2019 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.
Shares of Health Catalyst Inc. ran up 5.0% in afternoon trading Monday, after the Wall Street analysts who started coverage of the health data and analytics company were unanimously bullish. The company went public on July 25 at an initial public offering price of $26. Since closing that day at $39.17, the stock has now rallied 14%. In comparison, the Renaissance IPO ETF has shed 6.1% over the same time and the S&P 500 has declined 2.6%. All 7 analysts surveyed by FactSet who started covering Health Catalyst have the equivalent of buy ratings, while the average price target of $50.67 is 14% above current levels. Analyst Anne Samuel at J.P. Morgan, who initiated the company at overweight with a $50 stock price target, said Health Catalyst has less than 5% penetration of an $8 billion addressable market, "leaving significant runway for growth." SunTrust Robinson Humphrey's Sandy Draper started the company at buy with a $53 stock price target, citing an expected "long runway for growth," reinforced by an attractive revenue mix shift that should help improve gross margin as revenue grows.
SALT LAKE CITY , July 30 , 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...
SALT LAKE CITY , July 25, 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...
Salt Lake City, Utah-based Health Catalyst, Inc. plans to offer 7 million shares in an IPO to be priced between $24 and $25, according to a S-1/Afiling done on July 23. The company upsized the offering from the initially planned 6 million share as well as hiked the estimated price range from $20 to $23. The company's shares have been approved for listing on the Nasdaq under the ticker symbol HCAT.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...